Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Jasper Therapeutics, Inc. Jasper Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) December 18, 2023 From Jasper Therapeutics, Inc. Via GlobeNewswire Tickers JSPR Jasper Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update November 09, 2023 From Jasper Therapeutics, Inc. Via GlobeNewswire Tickers JSPR Jasper Therapeutics Reports Second Quarter 2023 Financial Results and Provides a Business Update August 11, 2023 From Jasper Therapeutics, Inc. Via GlobeNewswire Tickers JSPR Jasper Therapeutics Reports Third Quarter 2022 Financial Results and Provides a Corporate Update November 10, 2022 From Jasper Therapeutics, Inc. Via GlobeNewswire Tickers JSPR Jasper Therapeutics Closes Transaction With Amplitude Healthcare Acquisition Corporation, Creating a Publicly Traded Biotechnology Company Dedicated to Enabling Cures Through Hematopoietic Stem Cell Therapy September 24, 2021 From Jasper Therapeutics, Inc. Via Business Wire Jasper Therapeutics and Amplitude Healthcare Acquisition Corporation Announce Two New Board Members September 20, 2021 From Jasper Therapeutics, Inc. Via Business Wire Jasper Therapeutics Initiates New Clinical Trial with National Cancer Institute to Evaluate JSP191 in GATA2-related Myelodysplastic Syndromes September 08, 2021 From Jasper Therapeutics, Inc. Via Business Wire Jasper Therapeutics Announces Orphan Drug and Rare Pediatric Disease Designations for JSP191 for Conditioning Treatment Prior to Stem Cell Transplant June 14, 2021 From Jasper Therapeutics, Inc. Via Business Wire Jasper Therapeutics to Host Webcast to Review Updated 90-day Data from Phase 1 Clinical Trial of JSP191 That is Being Presented at 2021 ASCO Virtual Annual Meeting June 01, 2021 From Jasper Therapeutics, Inc. Via Business Wire Jasper Therapeutics Announces New Clinical Trial with the National Institute of Allergy and Infectious Diseases to Evaluate JSP191 in Chronic Granulomatous Disease May 26, 2021 From Jasper Therapeutics, Inc. Via Business Wire Jasper Therapeutics Announces Updated 90-day Data from Phase 1 Clinical Trial of JSP191 as Targeted Stem Cell Conditioning Agent in Older Patients with Myelodysplastic Syndromes or Acute Myeloid Leukemia Undergoing Hematopoietic Cell Transplantation May 19, 2021 From Jasper Therapeutics, Inc. Via Business Wire Jasper Therapeutics and Amplitude Healthcare Acquisition Corporation Announce Merger to Create a Publicly Listed Leading Biotechnology Company in Hematopoietic Stem Cell Transplantation May 06, 2021 From Jasper Therapeutics, Inc. Via Business Wire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.